Introduction to Adenosine Receptors as Therapeutic Targets

Abstract

Adenosine acts as a cytoprotective modulator in response to stress to an organ or tissue. Although short-lived in the circulation, it can activate four subtypes of G protein-coupled adenosine receptors (ARs): A₁, A_2A, A_2B, and A₃. The alkylxanthines caffeine and theophylline are the prototypical antagonists of ARs, and their stimulant actions occur primarily through this mechanism. For each of the four AR subtypes, selective agonists and antagonists have been introduced and used to develop new therapeutic drug concepts. ARs are notable among the GPCR family in the number and variety of agonist therapeutic candidates that have been proposed. The selective and potent synthetic AR agonists, which are typically much longer lasting in the body than adenosine, have potential therapeutic applications based on their anti-inflammatory (A_2A and A₃), cardioprotective (preconditioning by A₁ and A₃ and postconditioning by A_2B), cerebroprotective (A₁ and A₃), and antinociceptive (A₁) properties. Potent and selective AR antagonists display therapeutic potential as kidney protective (A₁), antifibrotic (A_2A), neuroprotective (A_2A), and antiglaucoma (A₃) agents. AR agonists for cardiac imaging and positron-emitting AR antagonists are in development for diagnostic applications. Allosteric modulators of A₁ and A₃ ARs have been described. In addition to the use of selective agonists/antagonists as pharmacological tools, mouse strains in which an AR has been genetically deleted have aided in developing novel drug concepts based on the modulation of ARs.